$ALZN
Alzamend Neuro, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121465924016346 Filed on September 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $755.8K $1.160M
YoY Change -34.84% -30.1%
% of Gross Profit
Research & Development $206.6K $2.366M
YoY Change -91.27% 71.96%
% of Gross Profit
Depreciation & Amortization $12.69K $12.69K
YoY Change 0.0% 78.74%
% of Gross Profit
Operating Expenses $962.4K $3.526M
YoY Change -72.7% 156.25%
Operating Profit -$962.4K -$3.526M
YoY Change -72.7% 16.15%
Interest Expense $12.01K $1.835K
YoY Change 554.28% 19.78%
% of Operating Profit
Other Income/Expense, Net -$12.01K -$1.835K
YoY Change 554.28% 19.78%
Pretax Income -$974.4K -$3.530M
YoY Change -72.4% 16.23%
Income Tax
% Of Pretax Income
Net Earnings -$974.4K -$3.528M
YoY Change -72.38% 16.16%
Net Earnings / Revenue
Basic Earnings Per Share -$1.25 -$0.04
Diluted Earnings Per Share -$1.25 -$0.04
COMMON SHARES
Basic Shares Outstanding 841.2K shares 96.94M shares
Diluted Shares Outstanding 777.8K shares 98.44M shares

Balance Sheet

Concept 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.194M $1.700M
YoY Change -29.77% -85.25%
Cash & Equivalents $1.194M $1.695M
Short-Term Investments
Other Short-Term Assets $222.2K $720.0K
YoY Change -69.13% 24.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.416M $2.414M
YoY Change -41.32% -80.08%
LONG-TERM ASSETS
Property, Plant & Equipment $253.7K $214.4K
YoY Change 18.31% 123.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $253.7K $214.4K
YoY Change 18.31% 123.77%
TOTAL ASSETS
Total Short-Term Assets $1.416M $2.414M
Total Long-Term Assets $253.7K $214.4K
Total Assets $1.670M $2.628M
YoY Change -36.46% -78.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.882M $2.741M
YoY Change 5.15% 166.44%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.882M $2.740M
YoY Change 5.19% 166.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.882M $2.740M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.882M $2.741M
YoY Change 5.15% 166.44%
SHAREHOLDERS EQUITY
Retained Earnings -$54.99M -$47.60M
YoY Change 15.53% 47.68%
Common Stock $86.00 $9.694K
YoY Change -99.11% 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.212M -$112.9K
YoY Change
Total Liabilities & Shareholders Equity $1.670M $2.628M
YoY Change -36.46% -78.48%

Cashflow Statement

Concept 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$974.4K -$3.528M
YoY Change -72.38% 16.16%
Depreciation, Depletion And Amortization $12.69K $12.69K
YoY Change 0.0% 78.74%
Cash From Operating Activities -$1.056M -$3.298M
YoY Change -67.99% 30.02%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $150.0K
YoY Change -40.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K -$147.2K
YoY Change -38.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.964M
YoY Change
NET CHANGE
Cash From Operating Activities -$1.056M -$3.298M
Cash From Investing Activities -$90.00K -$147.2K
Cash From Financing Activities $1.964M
Net Change In Cash $817.9K -$3.445M
YoY Change -123.74% 35.82%
FREE CASH FLOW
Cash From Operating Activities -$1.056M -$3.298M
Capital Expenditures $90.00K $150.0K
Free Cash Flow -$1.146M -$3.448M
YoY Change -66.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 alzm Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2024Q3 alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
usd
CY2023Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 alzm Conversion Of Series Convertible Preferred Stock
ConversionOfSeriesConvertiblePreferredStock
usd
CY2023Q3 alzm Fair Value Of Warrants Issued In Connection With Series Convertible Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
usd
CY2023Q3 alzm Conversion Of Note Payable And Accrued Interest Into Series B Convertible Preferred Stock
ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
usd
CY2024Q3 alzm Shares Available For Grant Options Granted
SharesAvailableForGrantOptionsGranted
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3 alzm Shares Available For Grant Options Exercised
SharesAvailableForGrantOptionsExercised
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2024Q3 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 103
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30326
CY2024Q3 dei City Area Code
CityAreaCode
(844)
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
722-6303
CY2024Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q3 dei Trading Symbol
TradingSymbol
ALZN
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
206571 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2366137 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
755834 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1159794 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
962405 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3525931 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-962405 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3525931 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
12006 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1835 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12006 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1835 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-974411 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3527766 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.38
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
777821 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
777821 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
656267 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
656267 shares
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2594185 usd
CY2024Q3 alzm Issuance Of Preferred Stock For Cash
IssuanceOfPreferredStockForCash
1963644 usd
CY2024Q3 alzm Conversion Of Note Payable And Interest To Preferred Stock
ConversionOfNotePayableAndInterestToPreferredStock
311356 usd
CY2024Q3 alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
81277 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-974411 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1212319 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3045503 usd
CY2023Q3 alzm Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
369380 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3527766 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-112883 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-974411 usd
CY2024Q3 us-gaap Depreciation
Depreciation
12685 usd
CY2023Q3 us-gaap Depreciation
Depreciation
12685 usd
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9286 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
81277 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
369380 usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
143047 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270599 usd
CY2023Q3 alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
-247334 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-41532 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-129234 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1055742 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3298200 usd
CY2024Q3 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
90000 usd
CY2023Q3 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
147243 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147243 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1963644 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1963644 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
817902 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3445443 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
376048 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5140859 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1193950 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1695416 usd
CY2024Q3 alzm Conversion Of Series Convertible Preferred Stock
ConversionOfSeriesConvertiblePreferredStock
624770 usd
CY2024Q3 alzm Fair Value Of Warrants Issued In Connection With Series Convertible Preferred Stock
FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock
510209 usd
CY2024Q3 alzm Conversion Of Note Payable And Accrued Interest Into Series B Convertible Preferred Stock
ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock
311356 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Cash
Cash
1200000 usd
CY2024Q3 alzm Working Capital Deficiency
WorkingCapitalDeficiency
1500000 usd
CY2024Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
55000000.0 usd
CY2024Q3 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
1200000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
1000000.0 usd
CY2024Q3 alzm Cash Used In Operating Activities
CashUsedInOperatingActivities
1100000 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zabrWuaw6wn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_869_zqm2IOOl3Sef">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
556045 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
189053 shares
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
209619 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
60522 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12622 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18672 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
222241 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
79194 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
62000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
98000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
178.12
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70500 usd
CY2024Q3 alzm Shares Available For Grant Options Expired
SharesAvailableForGrantOptionsExpired
3333 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3333 shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
150.00
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
65333 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
94667 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
179.11
CY2024Q3 alzm Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P5Y1M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35100 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
88001 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
179.39
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y10M28D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
35100 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
87043 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
178.72
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M17D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
35100 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
167 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
375.00
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
167 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
375.00
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
240449 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
67.45
CY2024Q3 alzm Class Of Warrant Or Right Outstanding Granted
ClassOfWarrantOrRightOutstandingGranted
200000 shares
CY2024Q3 alzm Weighted Average Exercises Price Granted
WeightedAverageExercisesPriceGranted
12.50
CY2024Q3 alzm Class Of Warrant Or Right Outstanding Cancelledexpired
ClassOfWarrantOrRightOutstandingCancelledexpired
-1570 shares
CY2024Q3 alzm Weighted Average Exercise Price Cancelledexpired
WeightedAverageExercisePriceCancelledexpired
450.14
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
438879 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
106.96
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
173333 shares
CY2024Q3 alzm Origination Fees
OriginationFees
125000 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50

Files In Submission

Name View Source Status
0001214659-24-016346-index-headers.html Edgar Link pending
0001214659-24-016346-index.html Edgar Link pending
0001214659-24-016346.txt Edgar Link pending
0001214659-24-016346-xbrl.zip Edgar Link pending
alzm-20240731.xsd Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
alzm-20240731_cal.xml Edgar Link unprocessable
alzm-20240731_def.xml Edgar Link unprocessable
alzm-20240731_lab.xml Edgar Link unprocessable
alzm-20240731_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
z9624010q.htm Edgar Link pending
z9624010q_htm.xml Edgar Link completed